Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm

被引:8
|
作者
Nishino, Mizuki [1 ,2 ]
Wakai, Satoshi [3 ]
Hida, Tomoyuki [1 ,2 ]
Dahlberg, Suzanne E. [4 ]
Ozaki, Masahiro [3 ]
Hatabu, Hiroto [1 ,2 ]
Tachizaki, Hisashi [3 ]
Johnson, Bruce E. [5 ,6 ,7 ]
机构
[1] Brigham & Womens Hosp, Dept Radiol, 450 Brookline Ave, Boston, MA 02215 USA
[2] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA
[3] Canon Med Syst Corp, 1385 Shimoishigami, Otawara, Tochigi 3248550, Japan
[4] Dana Farber Canc Inst, Dept Biostat, 450 Brookline Ave, Boston, MA 02215 USA
[5] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA
[6] Dana Farber Canc Inst, Dept Med, 450 Brookline Ave, Boston, MA 02215 USA
[7] Brigham & Womens Hosp, 450 Brookline Ave, Boston, MA 02215 USA
基金
美国国家卫生研究院;
关键词
Lung cancer; Epidermal growth factor receptor; EGFR inhibitor; Computed tomography; Tumor growth rate; DIFFERENT TREATMENT MODALITIES; RESPONSE EVALUATION CRITERIA; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; NSCLC PATIENTS; OPEN-LABEL; ERLOTINIB; CHEMOTHERAPY; GEFITINIB; PROGRESSION;
D O I
10.1016/j.ejrad.2018.10.014
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To develop an automated analytic module for calculation of tumor growth rate from serial CT scans and to apply the module and evaluate reproducibility in a pilot cohort of advanced NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors. Materials and methods: The module utilized a commercially available image-processing workstation equipped with a validated tumor volume measurement tool. An automated analytic software module was programmed with the capability to record and display serial tumor volume changes and to calculate tumor volume growth rate over time and added to the workstation. The module was applied to evaluate the tumor growth rate in a pilot cohort of 24 EGFR-mutant patients treated with EGFR inhibitors, and reproducibility references as tested by two independent thoracic radiologists. Results: The module analyzed chest CT scans from 24 patients (5 males, 19 females; median age: 61) with a median of 8 scans per patient, totaling 227 scans and provided a graphical display with an automated and instant calculation of tumor growth rate after the nadir volume for each patient. High inter and intraobserver agreements were noted for tumor growth rates, with concordance correlation coefficients of 0.9323 and 0.9668, respectively. Interpretation of slow versus fast tumor growth using previously identified threshold of <= 0.15/month had a perfect interobserver agreement (kappa = 1.00), and an excellent intraobserver agreement (kappa = 0.895). Conclusions: The present study describes the development of an image analytic module for assessing tumor growth rate and the data demonstrates the functionality and reproducibility of the module in a pilot cohort of EGFR-mutant NSCLC patients treated with EGFR-TKI. The image analytic module is an initial step for clinical translation of the tumor growth rate approach to guide cancer treatment in precision oncology.
引用
收藏
页码:68 / 76
页数:9
相关论文
共 50 条
  • [41] Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench
    Jin, Rui
    Zhao, Jing
    Xia, Lexin
    Li, Qin
    Li, Wen
    Peng, Ling
    Xia, Yang
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [42] Spatiotemporal T790M Heterogeneity in a Patient with EGFR-Mutant Non-Small-Cell Lung Cancer
    Hata, Akito
    Masago, Katsuhiro
    Katakami, Nobuyuki
    Imai, Yukihiro
    Yatabe, Yasushi
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (08) : E64 - E65
  • [43] Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy
    Akimasa Sekine
    Hiroaki Satoh
    Medical Oncology, 2017, 34
  • [44] Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
    Zhang, Shi-Ling
    Zhang, Chan -Yuan
    Chen, Yu-Qing
    Li, Yu -Fa
    Xie, Zhi
    Zhang, Xu-Chao
    Zhou, Qing
    Zhong, Wen-Zhao
    Huang, Jie
    Sun, Hao
    Zheng, Ming-Ying
    Xiao, Fa-Man
    Yan, Hong-Hong
    Lu, Dan-Xia
    Lv, Zhi-Yi
    Wu, Yi-Long
    Chen, Hua-Jun
    Yang, Jin-Ji
    JOURNAL OF THORACIC DISEASE, 2023, 15 (09) : 4620 - 4635
  • [45] Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy
    Sekine, Akimasa
    Satoh, Hiroaki
    MEDICAL ONCOLOGY, 2017, 34 (07)
  • [46] MRI radiomics predicts the efficacy of EGFR-TKI in EGFR-mutant non-small-cell lung cancer with brain metastasis
    Qi, H.
    Hou, Y.
    Zheng, Z.
    Zheng, M.
    Sun, X.
    Xing, L.
    CLINICAL RADIOLOGY, 2024, 79 (07) : 515 - 525
  • [47] Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer
    Zhu, Viola W.
    Klempner, Samuel J.
    Ou, Sai-Hong Ignatius
    TRENDS IN CANCER, 2019, 5 (11): : 677 - 692
  • [48] Management of EGFR-Mutant Non-Small Cell Lung Cancer: Focus on Gefitinib
    Naito, Yoichi
    Goto, Koichi
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1027 - 1040
  • [49] EGFR mutation analysis in non-small-cell lung cancer
    Tapia, C.
    Savic, S.
    Bihl, M.
    Rufle, A.
    Zlobec, I.
    Terracciano, L.
    Bubendorf, L.
    PATHOLOGE, 2009, 30 (05): : 384 - 392
  • [50] Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer
    Blaquier, Juan Bautista
    Ortiz-Cuaran, Sandra
    Ricciuti, Biagio
    Mezquita, Laura
    Cardona, Andres Felipe
    Recondo, Gonzalo
    CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3579 - 3591